The U.S. Food and Drug Administration has approved a new oral treatment for patients with advanced hormone receptor-positive breast cancer, offering another option for people whose disease has progressed. The decision follows encouraging results from a global phase 3 clinical trial, according to Reuters.

The approval expands the range of therapies available for a common form of breast cancer that can be difficult to manage once it becomes advanced. An oral drug can also reduce the need for some clinic-based treatments, which may matter to patients balancing frequent care with daily life.

Reuters reported that the trial data showed positive outcomes, supporting the regulator’s decision. While the new therapy is not a cure, approvals like this can give doctors additional tools to slow disease progression and improve treatment planning for patients and families.

Breast cancer remains a major health burden worldwide, and advances in targeted medicines continue to shape care for patients in later stages of the disease. The latest FDA action adds to that evolving treatment landscape.